Standard treatment of glioblastomas (GBMs) consists of microsurgical resection followed by concomitant chemoradiation. The extent of resection is one of the most important prognostic factors with significant influence on the survival of patients. State of the art technique to achieve the most radical resection possible in conventional surgery is fluorescence-guidance with 5-aminolevulinic acid (5-ALA). If available, intraoperative MRI (iMRI)-guided tumor resection enables an intraoperative resection control and subsequent continuation of surgery if contrast enhancing tumor remnants are found. Therefore a more radical resection and longer survival of patients might be possible. To date no comparison of these two leading technologies for GBM-surgery is available to identify the best surgical therapy of this fatal disease and to justify significant healthcare-economic differences between both technologies. Goal of this study is to assess the value of iMRI guidance in the resection of GBMs in comparison to conventional 5-ALA microsurgery. Primary endpoint is the number of total resections (no residual contrast enhancement) in the postoperative MRI (T1+CM within 48 hours after surgery) in each group. Secondary endpoints are perioperative clinical data, progression free survival, patients' clinical condition and overall survival. The study design was chosen to be a parallel-group approach to compare iMRI and 5-ALA centers (n=13) to exclude possible bias which might be found by randomizing patients within individual iMRI centers and to have surgeons with the most experience possible in use of each respective technology.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
315
For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
Department of Neurosurgery, Universitätsklinikum Bonn, Bonn, Germany
Bonn, Germany
Department of Neurosurgery, Universität zu Köln, Köln, Germany
Cologne, Germany
Städtisches Klinikum Dresden Friedrichstadt
Dresden, Germany
Department of Neurosurgery, Heinrich-Heine-Universität Düsseldorf, Düsseldorf
Düsseldorf, Germany
Department of Neurosurgery, Friedrich-Alexander-University Erlangen-Nürnberg
Erlangen, Germany
Department of Neurosurgery, Johann Wolfgang Goethe-University Frankfurt am Main
Frankfurt a.M., Germany
Department of Neurosurgery, Georg-August-Universität Göttingen, Göttingen,
Göttingen, Germany
Department of Neurosurgery, University of Ulm, Hospital Günzburg,
Günzburg, Germany
Asklepios Klinik Hamburg, Klinik für Neurochirurgie
Hamburg, Germany
International Neuroscience Institute Hannover, Hannover, Germany
Hanover, Germany
...and 5 more locations
Complete resections in the postoperative MRI (T1+/-CM) within 48 hours after surgery
Completeness of resection in the postoperative MRI within 48h after surgery. Blinded analysis by an independent radiologist.
Time frame: 48 hour
Patients' clinical condition (KPS)
-KPS clinical scoring
Time frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery
Patients' clinical condition (NIHSS)
-NIHSS stroke score
Time frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery
Patients' clinical condition (QoL)
-quality of life (EORTC) questionnaire
Time frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery
ICU and hospital stay after surgery
-ICU and overall hospital stay after surgery
Time frame: Time of hospital stay (average 7days)
Patients' adjuvant treatment
-adjuvant treatment each patient has received
Time frame: 3Months, 6Months, 9Months, 12Months after surgery
Recurrent tumor growth (RANO criteria)
-recurrent tumor growth (RANO criteria) according to local tumor boards and independent blinded analysis
Time frame: 3Months, 6Months, 9Months, 12Months after surgery
Follow-up imaging
-follow-up imaging 3, 6, 9, 12 months postoperative incl. independent blinded analysis
Time frame: 3Months, 6Months, 9Months, 12Months after surgery
Histology
Histological analysis
Time frame: 1 week after surgery
MGMT (O6-methylguanine-DNA-methyltransferase) analysis
MGMT promoter analysis (Routine molecular diagnostics)
Time frame: 1 week after surgery
IDH-1 (isocitrate dehydrogenase) analysis
IDH-1 mutation analysis (Routine molecular diagnostics)
Time frame: 1 week after surgery
Progression-free survival (PFS)
6M\&12M-PFS
Time frame: Day of surgery - 6 months - 12 months
Overall survival (OS)
OS of patients
Time frame: Day of surgery - Death of patient (Max. 10 years follow-up)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.